arrow
M

Marcus Lacerda

fundação oswaldo cruz
H指数:69
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil

巴西流行地区12个月、双盲、随机、安慰剂对照的III期试验中,一种减毒活疫苗的登革热病毒疫苗在青少年中的安全性和免疫原性的最终结果

2025-12-080
PRE
Dengue virus genetic diversity in unvaccinated and vaccinated dengue-infected individuals: an observational analysis of the Butantan-DV phase 3 trial in Brazil

登革病毒在未接种疫苗和接种疫苗的登革热感染者中的遗传多样性:巴西Butantan-DV三期试验的观察性分析

2025-11-290
OAAI
Nasopharyngeal Proteomic Profiles from Patients Hospitalized Due to COVID-19 in Manaus, Amazonas, Brazil

来自巴西亚马孙州马瑙斯因COVID-19住院患者的鼻咽部蛋白质组学图谱

2025-11-180
PRE
Heme and hemozoin induce platelet cell death through UPR-induced apoptosis and ferroptosis in vivax malaria

血红素和疟色素通过UPR诱导的凋亡和铁死亡途径在间日疟疾中诱导血小板细胞死亡

2025-10-220
OAAI
Autoantibodies Against Type I Interferons are a Prominent Feature in SARS-CoV-2 Fatal Disease and Hospitalization

抗I型干扰素自身抗体是SARS-CoV-2致死性疾病和住院的一个显著特征

2025-10-010
PRE
The cost-effectiveness of tafenoquine following screening with STANDARD™ G6PD screening for the treatment of vivax malaria in the Brazilian Public Health System

在巴西公共卫生系统中,使用STANDARD™ G6PD筛查后,泰非诺奎(tafenoquine)治疗间日疟的成本效益分析。

2025-09-020
PREAI
Towards Malaria Elimination: A Nationwide Case-Control Study to Assess Risk Factors for Severe Malaria-Related Deaths in Brazil

迈向疟疾消除:一项全国性病例对照研究,用于评估巴西严重疟疾相关死亡的风险因素

2025-09-010
OAAI
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study

Dolutegravir/Lamivudine双疗法在CD4计数<200/mm³初治人群中的疗效与安全性:DOLCE研究48周结果

2025-08-012
PRE
Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium Vivax in the Brazilian Amazon

CYP2D6、MAOA和UGT2B7基因变异对巴西亚马逊地区间日疟复发的影响

2025-05-020
OA
Decentralization of snakebite antivenom treatment to indigenous community health centers in the Brazilian Amazon: From demand to the first treatment (the SAVING Program)

巴西亚马逊地区蛇咬抗蛇毒血清治疗的去中心化:从需求到首次治疗(SAVING项目)

2025-04-300
OA
Association between cytokine and increased risk of death in ART- naïve and ART-non-adherence patients hospitalized with advanced HIV disease
2025-02-090
OAAI
Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM)
2025-01-090
PRE
Inflammatory discoveries two years after acute severe COVID-19: a longitudinal biomarker profile assessment in long COVID individuals in the Brazilian Amazon
2024-12-230
OAAI
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
2024-11-272
PRE
Spatially resolved single-cell atlas unveils a distinct cellular signature of fatal lung COVID-19 in a Malawian population
2024-11-201
OAAI
Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil

Butantan-DV在2-59岁参与者中的疗效和安全性: 来自巴西的双盲,随机,安慰剂对照,3期,多中心试验的结果

2024-11-012
PRE